Research Article
The Success of Treatment Free Remission in Chronic Myeloid Leukaemia in Clinical Practice: A Single-Centre Retrospective Experience from South Africa
Table 3
Profile of patients attempting treatment-free remission.
| | | Overall group | Successful | Unsuccessful |
| | Number | 12 | 9 | 3 | | Median age at diagnosis in years (range) | 51 (29–66) | 50 (29–66) | 53 (45–59) | | Median age at discontinuation in years (range) | 63 (44–82) | 63 (44–82) | 61 (52–67) | | Gender, n (%) | | Males | 3 (25) | 3 (33) | 0 | | Female | 9 (75) | 6 (67) | 3 (100) | | Sokal score, n (%) | | Low | 6 (50) | 5 (56) | 1 (33) | | Intermediate | 1 (8) | 1 (11) | N/A | | High | 3 (25) | 1 (11) | 2 (67) | | Indeterminate | 2 (17) | 2 (22) | N/A | | Median time of follow-up in months (range) | 12 (8–23) | 12 (8–23) | 12 (11–14) | | TKI at discontinuation, n (%) | | Imatinib | 11 (92) | 8 (89) | 3 (100) | | Nilotinib | 1 (8) | 1 (11) | 0 | | Reasons for TKI discontinuation, n (%) | | Shared∗ | 12 (100) | 9 (75) | 3 (25) | | Toxicity | 4 (33) | 2 (17) | 2 (17) | | Median total duration of TKI in months (range) | 133 (87–192) | 137 (87–192) | 96 (87–97) | | Median time to DMR in months (range) overall | 39 (13–89) | 42 (13–89) | 28 (13–54) | | MR4 (n − 2) | 72 (54–89) | 89 | 54 | | MR4.5 (n − 10) | 32 (13–61) | 36 (13–61) | 15 (13−17) | | Median duration of DMR in months (range) overall | 87 (33–148) | 99 (33–148) | 70 (43–82) | | MR4 (n − 2) | 40 (37–43) | 37 | 43 | | MR4.5 (n − 10) | 95 (33–148) | 99 (33–148) | 76 (70–82) |
|
|
TKI: tyrosine kinase inhibitor; DMR: deep molecular response; TFR: treatment-free remission; shared decision : agreement between treating physician and patient to discontinue TKI therapy. |
